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Exacerbated sensitivity to mechanical stimuli that are normally innocuous or mildly painful
(mechanical allodynia and hyperalgesia) occurs during inflammation and underlies painful
diseases. Proteases that are generated during inflammation and disease cleave protease-activated
receptor 2 (PAR2) on afferent nerves to cause mechanical hyperalgesia in the skin and intestine
by unknown mechanisms. We hypothesized that PAR2-mediated mechanical hyperalgesia
requires sensitization of the ion channel transient receptor potential vanilloid 4 (TRPV4).
Immunoreactive TRPV4 was coexpressed by rat dorsal root ganglia (DRG) neurons with PAR2,
substance P (SP) and calcitonin gene-related peptide (CGRP), mediators of pain transmission.
In PAR2-expressing cell lines that either naturally expressed TRPV4 (bronchial epithelial cells) or
that were transfected to express TRPV4 (HEK cells), pretreatment with a PAR2 agonist enhanced
Ca2+ and current responses to the TRPV4 agonists phorbol ester 4α-phorbol 12,13-didecanoate
(4αPDD) and hypotonic solutions. PAR2-agonist similarly sensitized TRPV4 Ca2+ signals
and currents in DRG neurons. Antagonists of phospholipase Cβ and protein kinases A, C
and D inhibited PAR2-induced sensitization of TRPV4 Ca2+ signals and currents. 4αPDD and
hypotonic solutions stimulated SP and CGRP release from dorsal horn of rat spinal cord,
and pretreatment with PAR2 agonist sensitized TRPV4-dependent peptide release. Intraplantar
injection of PAR2 agonist caused mechanical hyperalgesia in mice and sensitized pain responses
to the TRPV4 agonists 4αPDD and hypotonic solutions. Deletion of TRPV4 prevented PAR2
agonist-induced mechanical hyperalgesia and sensitization. This novel mechanism, by which
PAR2 activates a second messenger to sensitize TRPV4-dependent release of nociceptive peptides
and induce mechanical hyperalgesia, may underlie inflammatory hyperalgesia in diseases where
proteases are activated and released.
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The ability to detect mechanical stimuli allows organisms
to respond to their environment. High-intensity
mechanical stimuli can damage tissue and provoke
pain, leading to avoidance behaviours. Inflammatory
mediators enhance sensitivity to mechanical stimuli that
are normally innocuous or mildly painful (mechanical
allodynia or hyperalgesia, respectively), resulting in pain
associated with disorders such as arthritis, inflammatory
bowel disease and irritable bowel syndrome. However,
the ion channels that transduce mechanical stimuli are
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not unequivocally identified, and the mechanisms by
which inflammation causes mechanical allodynia and
hyperalgesia are incompletely understood. Consequently,
the treatments for these painful conditions are inadequate.
Proteases are prominent mediators of inflammation
and pain. Injury, inflammation and disease trigger
the production of numerous serine proteases from
the circulation (e.g. coagulation factors), inflammatory
cells (e.g. mast cell tryptase, neutrophil cathepsin G)
and epithelial tissues (e.g. trypsin IV, kallikreins) that
regulate cells by cleaving protease-activated receptors
(PARs), a family of four G protein-coupled receptors
(Ossovskaya & Bunnett, 2004). Proteolysis unmasks a
tethered ligand domain, which binds to and activates
the receptor. This irreversible mechanism of activation
controls haemostasis, inflammation, pain and repair after
tissue injury. PAR2, a receptor for trypsins (Nystedt
et al. 1994; Bohm et al. 1996b; Cottrell et al. 2004),
tryptase (Corvera et al. 1997; Molino et al. 1997),
coagulation factors FVIIa and FXa (Camerer et al. 2000)
and kallikreins (Oikonomopoulou et al. 2006), is an
important proinflammatory and nociceptive mediator.
PAR2 is expressed by primary spinal afferent neurons of
dorsal root ganglia (DRG) containing the neuropeptides
substance P (SP) and calcitonin gene-related peptide
(CGRP) (Steinhoff et al. 2000). These neurons contribute
to neurogenic inflammation and nociception. Agonists of
PAR2 (e.g. tryptase, secreted by mast cells adjacent to nerve
fibres) stimulate the release of SP and CGRP from afferent
nerves (Steinhoff et al. 2000). When released from peri-
pheral nerve endings in the skin and intestine, SP and
CGRP cause plasma extravasation, granulocyte infiltration
and hyperaemia (i.e. neurogenic inflammation) (Steinhoff
et al. 2000; Cenac et al. 2003; Nguyen et al. 2003). PAR2
agonists also stimulate peptide release from the central
endings of afferent nerves in the dorsal horn of the
spinal cord, to cause thermal and mechanical hyperalgesia
(Vergnolle et al. 2001; Coelho et al. 2002). This thermal
hyperalgesia depends on sensitization of the transient
receptor potential vanilloid 1 (TRPV1) ion channel, which
enhances the activity of nociceptive fibres and consequent
peptide release (Amadesi et al. 2004, 2006; Dai et al. 2004).
The mechanism of PAR2-induced mechanical hyperalgesia
is unknown.
TRPV4, the mammalian homologue of the C. elegans
gene Osm-9 (Liedtke et al. 2003), is a potential
mediator of mechanical hyperalgesia. TRPV4 is gated
by altered tonicity and by temperatures >27◦C (Liedtke
et al. 2000; Guler et al. 2002). Hypo-osmotic stimuli
cause cell swelling, phospholipase A2 activation and
generation of arachidonic acid (Pedersen et al. 2000).
A cytochrome P450 product of arachidonic acid,
5′,6′-epoxyeicosatrienoic acid, activates TRPV4 and is a
potential endogenous agonist (Watanabe et al. 2003). The
phorbol ester 4α-phorbol 12,13-didecanoate (4αPDD)
is a synthetic TRPV4 agonist (Watanabe et al. 2002).
The expression of TRPV4 by neurosensory structures,
including circumventricular organs, inner ear hair cells,
Merkel cells and sensory neurons, and its activation by
hypotonic stimuli, suggest that it functions to detect
osmotic and mechanical stimuli. TRPV4−/− mice show
abnormal osmotic regulation and decreased nociceptive
responses to pressure (Liedtke & Friedman, 2003; Suzuki
et al. 2003), and TRPV4 knockdown or deletion reduces
nociceptive responses to hypotonic and mildly hypertonic
stimuli (Alessandri-Haber et al. 2003, 2005). Moreover,
inflammatory agents can sensitize TRPV4 by mechanisms
that are not fully characterized (Alessandri-Haber et al.
2003, 2006), suggesting that this channel mediates
inflammatory hyperalgesia.
We examined the hypothesis that PAR2 agonists sensitize
TRPV4 and thereby enhance release of SP and CGRP in
the dorsal horn of the spinal cord to cause mechanical
hyperalgesia. To do so we (a) determined if PAR2
agonists sensitize TRPV4 Ca2+ signals and currents in
cell lines and DRG neurons; (b) characterized signalling
pathways that mediate sensitization; (c) examined whether
TRPV4 is expressed in nociceptive neurons with PAR2,
SP and CGRP; (d) determined if PAR2 agonists sensitize
TRPV4-induced SP and CGRP release in the spinal cord;




Sprague-Dawley rats (male, 200–300 g) and C57BL6 mice
(male, 20–25 g) were from Charles River Laboratories
(Wilmington, MA). TRPV4+/+ and TRPV4−/− mice
(male, 20–30 g) have been described (Liedtke & Friedman,
2003). Institutional Animal Care and Use Committees
approved all procedures. Animals were killed by
sodium pentobarbital (200 mg kg−1, i.p.) and bilateral
thoracotomy.
Agonists and antagonists
Peptides corresponding to the tethered ligand domains
of PARs (activating peptides, APs) can selectively activate
these receptors, whereas the reverse sequences (reverse
peptides, RPs) are inactive control reagents. Mouse/
rat PAR2-AP (SLIGRL-NH2) and inactive PAR2-RP
(LRGILS-NH2) were from SynPep Corp. (Dublin, CA,
USA). The PAR1-selective agonist Xenopus PAR1-AP
(TFLLRN-NH2) and inactive PAR1-RP (NRLLFT-
NH2) were from Sigma Genosys (Woodland, TX, USA).
Capsaicin, 4αPDD, H-89 (N-[2-((p-bromocinnamyl)-
amino)ethyl]-5-isoquinolinesulphonamide) and
calphostin C were from Sigma (St Louis, MO, USA).
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GF109203X (bisindolylmaleimide I), Go¨6976 and Go¨6983
were from Calbiochem (La Jolla, CA, USA). U73122 was
from Tocris (Ellisville, MO, USA).
TRPV4 and PAR2 RT-PCR and TRPV4 cloning
Total RNA was extracted from 16HBE14o− (HBE)
cells and rat and mouse DRG (T12-L6) using Trizol®.
(Invitrogen, Carlsbad, CA, USA). RNA was reverse
transcribed with oligo(dT)12-18 or random hexamers and
avian myeloblastosis virus reverse transcriptase (Promega,
Madison, WI, USA) or TaqMan® reverse transcription
reagents (Applied Biosystems, Foster City, CA, USA).
Control reactions omitted reverse transcriptase. Products
were amplified using primers specific to human, rat and
mouse TRPV4 or human PAR2 (human TRPV4: forward
5′-ACATGCGGGAGTTCATTAAC-3′, reverse 5′-CACAG-
CCAGCATCTCGTGGCG-3′; rat TRPV4: forward 5′-TG-
GGAGGTATCACCCTTCTG-3′, reverse 5′-AGCCAG-
CATCTCATGGCG-3′; mouse TRPV4: forward
5′-ATCAACTCGCCCTTCAGAGA-3′, reverse 5′-CCCAA-
ACTTACGCCACTTGT-3′; human PAR2: forward
5′-CCCTTTGTATGTCGTGAAGCAGAC-3′, reverse
5′-TTCCTGGAGTGTTTCTTTGAGGTG-3′). Products
were separated by electrophoresis (2% agarose gel),
detected using ethidium bromide and sequenced to
confirm identity. Human TRPV4 was cloned by PCR from
HBE cells using the primers forward 5′-ATTGGATCC-
CCACCATGGCGGATTCCAGCGAAGG-3′ and reverse
5′-AATCTCGAGCTAGAGCGGGGCGTCATCAGTCC-3′.
An HA.11 tag was added to the C-terminus of human
TRPV4 by PCR using the primer 5′-AATCTCGAG-
CTAGGCGTAGTCGGGCACGTCGTAGGGGTAGAGC-
GGGGCGTCATCAGTCC-3′. The PCR product was sub-
cloned into the HindIII and XhoI sites of pcDNA5/FRT
or the tetracycline-inducible vector pcDNA5/FRT/TO
(Invitrogen, Carlsbad, CA, USA).
Cell lines
The human bronchial epithelial cell line 16HBE14o-
(HBE) was maintained in Modified Eagle’s Medium
(MEM) supplemented with 10% fetal bovine serum,
penicillin (100 u ml−1) and streptomycin (100 µg ml−1).
Human embryonic kidney (HEK) 293 cells were
maintained in MEM with 10% fetal bovine serum.
Cells were grown in 95% air, 5% CO2 at 37◦C.
HEK cells were transiently transfected with TRPV4
using Lipofectamine2000 (Invitrogen) and designated
HEK-TRPV4 cells. A tetracycline-inducible system was
used to generate stable cell lines expressing TRPV4, since
continuous overexpression of this channel was toxic
to cells. HEK-FLPTREX cells were stably transfected
with pcDNA5/FRT/TO + hTRPV4 (designated
HEK-FLPTREX-TRPV4 cells) and grown in Dulbecco’s
Modified Eagle’s Medium (DMEM) containing 10%
tetracycline-free fetal bovine serum, hygromycin
(50 µg ml−1) and blasticidin (10 µg ml−1). To induce
TRPV4 expression, tetracycline (0.1 µg ml−1) was added
to the medium 16 h before use.
Dispersion and culture of rat DRG neurons
DRG from thoracic and lumbar spinal cord of rats were
minced in cold Hanks’ Balanced Salt Solution (HBSS) and
incubated for 60–90 min at 37◦C in DMEM containing
0.5 mg ml−1 of trypsin, 1 mg ml−1 of collagenase type IA
and 0.1 mg ml−1 of DNAse type IV (Sigma) (Steinhoff et al.
2000). Soybean trypsin inhibitor (Sigma) was added to
neutralize trypsin. Neurons were pelleted, suspended in
DMEM containing 10% fetal bovine serum, 10% horse
serum, 100 u ml−1 penicillin, 0.1 mg ml−1 streptomycin,
2 mm glutamine and 2.5 µg ml−1 DNAse type IV, plated
on glass coverslips coated with Matrigel (BD Biosciences,
Bedford, MA, USA), and cultured for 2–3 days.
Dispersion and culture of mouse DRG neurons
DRG from thoracic and lumbar spinal cord of mice were
minced in cold HBSS, incubated for 15 min at 37◦C in
HBSS containing 0.5% papain, washed with Leibovitz’s
L-15 medium (supplemented with 2 mm glutamine, 0.2%
glucose and 2.5% fetal bovine serum), and incubated for
10 min at 37◦C in HBSS containing 1 mg ml−1 collagenase
type I and 4 mg ml−1 dispase II (Sigma). Neurons were
pelleted, suspended in DMEM containing 2.5% fetal
bovine serum, 1% penicillin/streptomycin, 1% dextrose,
2 mm glutamine and 10 µm of arabinocytidine hydro-
chloride, floxuridine and uridine. Neurons were plated in
poly l-orthinine-laminine-treated glass-bottomed dishes
and studied immediately.
Immunofluorescence
HEK cells (transiently transfected with wild-type or
HA.11-tagged TRPV4 or vector without insert) and
cultured rat DRG were fixed in 4% paraformaldehyde
in 100 mm PBS pH 7.4, for 20 min at 4◦C. Rats were
transcardially perfused with 4% paraformaldehyde in
100 mm PBS pH 7.4. DRG and spinal cord (L3–L6) were
removed and fixed in 4% paraformaldehyde for 6 h at
room temperature. Tissues were washed, incubated in
25% sucrose in PBS overnight at 4◦C, and embedded in
OCT. Sections of DRG (16–18 µm) were cut and mounted
on poly l-lysine-coated slides. Sections of spinal cord
(16 µm) were processed as floating sections. Cultured
cells were washed and incubated with 100 mm PBS,
pH 7.4 containing 1% normal goat serum and 0.1%
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saponin. Tissue sections were washed and incubated in
100 mm PBS, pH 7.4, containing 5% normal goat serum
and 0.3% Triton X-100. Cells and tissues were incubated
with the following primary antibodies: rat anti-HA.11
(Roche, IN; 1 : 1000); rabbit anti-TRPV4 (Alomone, Israel;
1 : 750); mouse anti-PAR2 (SAM11, Santa Cruz, CA, USA;
1 : 250); mouse anti-CGRP (no. 4901, CURE-UCLA, CA;
1 : 500); guinea pig antisubstance P (Chemicon, Temecula,
CA, USA; 1 : 1000) (all overnight, 4◦C). In controls,
the TRPV4 antiserum was preabsorbed by preincubation
with the antigen (10 µm, 24 h, 4◦C) before staining.
Cells and tissues were washed and incubated with goat
antirat, antirabbit, antimouse or antiguinea pig IgG
conjugated to fluorescein isothiocyanate or rhodamine
red X (Jackson Immuno-Research, West Grove, PA, USA;
1 : 200; 2 h, room temperature). Specimens were mounted
in Vectashield (Vector Laboratories, Burlingame, CA,
USA) for cultured cells or Prolong Gold (Invitrogen) for
tissue sections.
Confocal microscopy
Specimens were observed using a Zeiss Axiovert micro-
scope with a Bio-Rad MRC1000 confocal microscope and
Zeiss Fluar Plan Apo ×40 (NA 1.4) or ×100 (NA 1.3)
objectives. Images were collected with an iris of <3, zoom
of 1–2 and typically 5–10 optical sections were taken at
intervals of 0.5–1.0 µm. Presented images are single optical
sections. Images were processed to adjust contrast and
brightness and were coloured to represent appropriate
fluorophores, using Adobe Photoshop 7.0 (Adobe Systems,
Mountain View, CA, USA). Images of stained and control
slides were collected and processed identically.
Western blotting
HEK-TRPV4a cells were washed with ice-cold PBS,
scraped into 300 µl lysis buffer (50 mm Tris/HCl, 1% SDS,
pH 7.4), boiled and centrifuged. Protein concentration in
the supernatant was measured by BCA assay. Samples
(10 µg protein) were separated by SDS-PAGE (8% gel),
and transferred to Immobilon-FL membrane (Millipore,
Billerica, MA, USA). Membranes were incubated over-
night with rat anti-HA.11 (Roche, Indianapolis, IN;
1 : 5000), washed, and incubated for 1 h with goat
antirat AlexaFluor680 antibody (Invitrogen, 1 : 20 000).
Immunoreactive protein was detected using a Licor
Odyssey Scanner (Licor, Lincoln, NE, USA).
Measurement of [Ca2+]i in cell lines
HBE and HEK-TRPV4 cells grown on poly d-lysine-coated
coverslips were washed and incubated in HBSS (pH 7.4)
containing Ca2+ and Mg2+, 20 mm Hepes buffer, 0.1%
BSA, 100 u ml−1 penicillin, 100 µg ml−1 streptomycin,
with 2.5 µm Fura-2AM (Invitrogen) for 20 min at 37◦C.
Cells were washed, and fluorescence was measured at
340 nm and 380 nm excitation and 510 nm emission
in an F-2500 spectrophotometer (Hitachi Instruments,
San Jose, CA, USA). Test substances were injected
directly into the chamber (20 µl into 2 ml). Cells were
challenged once with 4αPDD (0.1–10 µm) or osmotic
stimuli (310–260 mosmol l−1), or were pretreated with
PAR2-AP, PAR2-RP, PAR1-AP or PAR1-RP (100 µm)
for 5 min followed by 4αPDD or osmotic stimuli. In
some experiments, cells were pretreated for 30 min with
inhibitors (U73122, 10 µm; H-89, 10 µm; GF109203X,
10 µm; Go¨6976, 0.1 µm; Go¨6983, 0.1 µm) or vehicle
(control) before the challenge with the test compound.
In experiments where inhibitors were used, cells were
pretreated with PAR2-AP or PAR2-RP for 10 min before
TRPV4 agonists, since some inhibitors (e.g. GF109203X)
delayed the return of [Ca2+] to baseline after stimulation
with PAR2 agonist. Results are expressed as the 340/380 nm
emission ratio, which is proportional to the [Ca2+]i.
Measurement of [Ca2+]i in DRG neurons
Rat DRG neurons grown on Matrigel-coated coverslips for
2–3 days after isolation were incubated in HBSS (pH 7.4)
containing Ca2+ and Mg2+, 20 mm Hepes, 0.1% BSA
with 5 µm of Fura-2AM for 45 min at 37◦C. Coverslips
were mounted in an open chamber at room temperature.
Fluorescence of individual cells was measured at 340 nm
and 380 nm excitation and 510 nm emission using a Zeiss
Axiovert microscope, an ICCD video camera (Stanford
Photonics, Stanford, CA, USA) and a video microscopy
acquisition program (Axon Instruments, Inc, Union City,
CA, USA). Test substances were directly added to the
chamber (50 µl into 350 µl). Neurons were preincubated
with PAR2-AP or PAR2-RP (10 µm) for 20 min followed
by 4αPDD (10 µm). In some experiments, cells were
pretreated for 30 min with inhibitors (GF109203X, 1 µm;
H-89, 10 µm) or vehicle (control) before the challenge with
the test compound. DRG preparations were challenged
with KCl at the end of each experiment, to identify neurons.
Results are expressed as the 340/380 nm emission ratio.
Electrophysiology in DRG neurons
Whole-cell membrane currents of freshly dispersed mouse
DRG neurons were recorded using an Axopatch 200B
amplifier (Molecular Devices, Sunnyvale, CA, USA). The
pipette solution contained (mm): 110 CsCl, 3 MgCl2, 10
EGTA, 10 Hepes, 3 Mg-ATP, 0.6 GTP, pH 7.2 with CsOH,
315 mosmol l−1. The extracellular solution contained
(mm): 120 NaCl, 5 KCl, 5 CaCl2, 2 MgCl2, 10 glucose, 10
Hepes, pH 7.4 with NaOH, 310 mOsm. Pipette resistance
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was 2–4 M	. Whole-cell currents were recorded and
analysed using Clampfit 9.2 software (Molecular Devices,
Sunnyvale, CA, USA). Neurons were held at 0 mV to
inactivate voltage-gated calcium and sodium channels,
and a 150 ms linear ramp protocol was applied (−100 mV
to +100 mV every 15 s). Current amplitude at −80 and
+80 mV was normalized to cell capacitance to obtain
current densities. Cells that did not display any detectable
whole-cell currents were not included in the analysis.
Sampling frequency for acquisition was 10 kHz, and
data were filtered at 2 kHz. Neurons were preincubated
with PAR2-AP (10 µm) or vehicle for 20 min, and then
challenged with 4αPDD (10 µm).
Electrophysiology in HEK-FLPTREX-TRPV4a cells
Whole-cell membrane currents of HEK-FLPTREX-
TRPV4a cells were recorded using an Axopatch 200B
amplifier (Molecular Devices, Sunnyvale, CA, USA) as
described (Amadesi et al. 2006). The pipette solution
contained (mm): KCl 140, MgCl2 3, EGTA 5, Hepes 5,
and ATPNa2 5. The external solution contained (mm):
NaCl 150, CaCl2 2, KCl 6, MgCl2 1, glucose 10, and
Hepes 10. Patch pipette resistance was 2–5 M	, and the
input resistance of the HEK-FLPTREX-TRPV4a cells was
1–10 G	. Whole-cell currents were recorded at room
temperature (∼23◦C) using Clampex 9.2 software, and
analysed using Clampfit 9.2 software (Molecular Devices).
The recording chamber was continuously superfused with
the external solution at approximately 2 ml min−1, and
rapid application of agonists in the external solution was
made using an eight-barrelled fast-flow device. Membrane
currents elicited by a linear ramp protocol from −100 mV
to +100 mV (holding voltage 0 mV) repeated every 15 s
were monitored at baseline and for 10 min following
application of 4αPDD (0.5 µm). PAR2-AP (100 µm) was
applied for 2 min. Current amplitudes were measured
at −80 mV and +80 mV in the ramp protocol from
the maximal response to 4αPDD, and corrected for cell
capacitance. In some experiments, calphostin C (2 µm) or
H-89 (3 µm) were added to the pipette solution.
Neuropeptide release from the dorsal horn
of the spinal cord
The spinal cords of rats were removed and slices
(0.4 mm) from the dorsal part of the cervical and
lumbar enlargements (without DRG) were prepared at
4◦C (Amadesi et al. 2006). Slices (∼100 mg) were placed
in 2 ml chambers and superfused with oxygenated (95%
O2, 5% CO2) Krebs’ solution (mm: NaCl 119, NaHCO3
25, KH2PO4 1.2, MgSO4 1.5, CaCl2 2.5, KCl 4.7 and
d-glucose 11) maintained at 37◦C and containing 0.1%
BSA, 1 µm phosphoramidon and 1 µm captopril. After a
60 min stabilization period, 5 min fractions were collected
into acetic acid (2 m final concentration). Tissues were
stimulated with 4αPDD (10 or 100 µm) or hypotonic
solution (228 mosmol l−1). In some experiments, slices
were perfused with Ca2+-free medium containing 1 mm
EGTA, or afferent nerves were depleted of neuropeptides
by preincubation with 10 µm capsaicin for 20 min before
stimulation. To determine if PAR2 sensitizes TRPV4
responses, slices were pretreated with PAR2-AP, PAR2-RP
(10 µm) or vehicle for 20 min, washed and then challenged
with TRPV4 agonists 20 min later. Freeze-dried fractions
were reconstituted with assay buffer and analysed by
enzyme immunoassays for CGRP and SP (Amadesi et al.
2006).
Paw withdrawal to mechanical stimuli
Mice were acclimatized for 15–20 min in a transparent box
with a metal mesh floor (Alessandri-Haber et al. 2006).
A calibrated von Frey hair monofilament (0.173 mN)
(Stoelting Company, Wood Dale, IL, USA) was applied
through the mesh floor to the plantar skin of the
hindpaw. Paw withdrawal was assessed as the number
of times the hind paw was withdrawn in response to
five applications of the von Frey hair, expressed as a
percentage (e.g. three withdrawals out of five was recorded
as 60%). Basal measurements were made for all mice.
After 15 min, PAR2-AP, 4αPDD or hypotonic solution
was injected (10 µl intraplantar injection), and paw
withdrawal measurements repeated immediately. After
an additional 5 min, 4αPDD or hypotonic solution was
injected into paws previously treated with PAR2-AP, and
paw withdrawal measurements repeated immediately.
Statistical analysis
Results are expressed as mean ± s.e.m. and were compared
by Student’s t test or ANOVA with Bonferroni’s or
Dunnett’s post hoc test. Differences were considered
significant when P < 0.05.
Results
Epithelial cells express TRPV4 and PAR2
PAR2-induced sensitization of TRPV4 can be conveniently
studied in cell lines expressing both proteins. Therefore,
we determined whether epithelial cell lines coexpressed
PAR2 and TRPV4. Transcripts corresponding to PAR2
(316 bp) were amplified by RT-PCR from the human
bronchial epithelial cell line HBE (Fig. 1A, lane 1). Three
isoforms of TRPV4 were amplified (Fig. 1A, lane 3), cloned
and sequenced: full-length TRPV4a, TRPV4b (lacking
amino acids 384–443, partially deleting the third of
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three ankyrin repeat domains), and TRPV4c (lacking
amino acids 237–283, corresponding to the first ankyrin
repeat domain) (Fig. 1B). These isoforms correspond to
reported sequences of TRPV4 (Arniges et al. 2006). Each
isoform, tagged with a C-terminal HA.11 epitope for
detection, was expressed in HEK cells, which naturally
express PAR2 (Amadesi et al. 2004). TRPV4a, TRPV4b
and TRPV4c were detected at the plasma membrane and
in intracellular locations by immunofluorescence using
Figure 1. Expression of TRPV4 in HBE cells and HEK cells
A, RT-PCR of HBE cells showing amplification of transcripts for PAR2
and TRPV4 isoforms a, b and c There were no signals when reverse
transcriptase (RT) was omitted (control). B, structure of three TRPV4
isoforms cloned from HBE cells. C, transient expression of TRPV4
isoforms with HA.11 tag in HEK cells. Immunoreactive TRPV4 was
detected by immunofluorescence (left) and Western blotting (right)
using HA.11 antibody. vc, vector control without TRPV4 insert. Scale
bar = 10 µm.
the HA.11 antibody (Fig. 1C, left panel). There was no
detectable signal in HEK cells expressing vector without
insert, confirming specificity. Western blotting confirmed
expression of TRPV4a with the anticipated size (98 kDa)
(Fig. 1C, right panel).
Since TRPV4 is a non-selective cation channel with
preference for Ca2+ ions, measurement of [Ca2+]i can be
used to assess channel activity. To confirm expression of
functional TRPV4 by HBE cells, we examined the effects
of the TRPV4 agonists 4αPDD and hypotonic stimuli
on [Ca2+]i (Liedtke et al. 2000; Watanabe et al. 2002).
4αPDD (1–10 µm) stimulated a concentration-dependent
increase in [Ca2+]i over 250 s (Fig. 2A, upper panel). A
decrease in osmolarity from 310 to 290 or 260 mosmol l−1
caused a tonicity-dependent increase in [Ca2+]i over a
similar period (Fig. 2A, lower panel). To confirm that
these responses are mediated by TRPV4, we expressed
the TRPV4 isoforms in HEK cells (Fig. 1C). 4αPDD
(0.1–1 µm) and a hypotonic stimulus (260 mosmol l−1)
caused graded increases in [Ca2+]i in HEK-TRPV4a cells
(Fig. 2B). There were no detectable responses in HEK cells
expressing TRPV4b, TRPV4c or empty vector (Fig. 2B).
Thus, 4αPDD and hypotonic stimuli increase [Ca2+]i in
HBE and HEK-TRPV4a cells, and the response of HEK
cells requires expression of the full-length TRPV4 channel.
Although multiple mechanisms can increase [Ca2+]i, these
data suggest that 4αPDD and hypotonic stimuli increase
[Ca2+]i by activating TRPV4.
PAR2 sensitizes TRPV4 Ca2+ signalling in HBE
and HEK-TRPV4a cells
Inflammatory mediators, including PAR2 agonists,
sensitize TRPV1 to cause thermal hyperalgesia (Lopshire
& Nicol, 1997; Chuang et al. 2001; Tominaga et al.
2001; Vellani et al. 2001; Amadesi et al. 2004, 2006;
Dai et al. 2004). Inflammatory agents also sensitize
TRPV4, though the precise mechanism remains unclear
(Alessandri-Haber et al. 2003, 2006). To examine whether
PAR2 agonists sensitize TRPV4, we measured their effects
on Ca2+ responses to 4αPDD and a hypotonic stimulus
in HBE cells. Pretreatment of HBE cells for 5 min with
PAR2-AP (100 µm) increased the magnitude of Ca2+
responses to 4αPDD (1 µm) or a hypotonic stimulus
(260 mosmol l−1) compared to pretreatment with inactive
PAR2-RP (100 µm, control) or vehicle, indicative of
sensitization (Fig. 3A). PAR2-AP similarly sensitized Ca2+
responses to 4αPDD (0.1 µm) or hypotonic stimulus
(260 mosmol l−1) in HEK-TRPV4a cells (Fig. 3B). Similar
results were obtained whether cells were pretreated with
PAR2-AP for 5 min (Fig. 3A and B) or 10 min (Fig. 4A–C)
before challenge with the TRPV4 agonists. After 10 min,
Ca2+ responses to PAR2-AP had returned to baseline. Thus,
pretreatment of epithelial cells with a selective agonist of
PAR2 sensitizes Ca2+ signals to TRPV4 agonists.
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We examined the selectivity of TRPV4 sensitization by
studying responses in cells pretreated with an agonist of
PAR1. In contrast to PAR2, agonists of PAR1 do not sensitize
TRPV1 (Amadesi et al. 2004), and induce analgesia rather
than hyperalgesia to thermal or mechanical stimuli (Asfaha
et al. 2002). We therefore determined if PAR1-selective AP
sensitized TRPV4 in HEK cells, which naturally express
this receptor (Amadesi et al. 2004). Although PAR1-AP
strongly increased [Ca2+]i in HEK-TRPV4a cells, it did
not sensitize responses to 4αPDD (Fig. 3C) or a hypotonic
Figure 2. Activation of TRPV4 in HBE cells and HEK cells
Effects of 4αPDD (0.1–10 µM, upper traces) and hypotonic stimuli (260–310 mosmol l−1, lower traces) on [Ca2+]i
in HBE cells (A) and HEK cells transiently expressing TRPV4 isoforms a, b or c or vector control (B). Left panels
show records of [Ca2+]i expressed as 340/380 nm emission ratio as a percentage of response measured at 50 s
(prestimulus, 100%). Right panels show [Ca2+]i responses as difference in 340/380 nm emission ratio between
50 s (prestimulus) and 300 s (maximal response). 4αPDD and hypotonic stimuli caused graded increases in [Ca2+]i
in HBE cells and HEK-TRPV4a cells, but had no effect in HEK cells expressing b or c TRPV4 isoforms or vector control.
∗P < 0.05, ANOVA and Dunnett’s test, n = 9 experiments.
stimulus (not shown) compared to PAR1-RP or vehicle.
HBE cells did not respond to PAR1-AP (100 µm), and thus
do not express functional PAR1 (data not shown). Thus,
activation of PAR2 but not PAR1 sensitizes TRPV4.
Phospholipase Cβ and protein kinases A, C and D
mediate PAR2-induced sensitization of TRPV4
Second messenger kinases including protein kinases A
(PKA), C (PKC) and D (PKD) can phosphorylate TRPV1
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to modify channel gating and thereby mediate hyper-
algesia to inflammatory stimuli (Lopshire & Nicol, 1998;
Premkumar & Ahern, 2000; Vellani et al. 2001; Bhave
et al. 2002; Mohapatra & Nau, 2003; Wang et al.
2004). The mechanism of PAR2-induced sensitization of
TRPV4 is unknown. Since PAR2 is known to couple to
phospholipase Cβ (PLCβ) (Bohm et al. 1996a) and to
activate PKC, PKA (Amadesi et al. 2006) and PKD (
N.W. Burnett, unpublished observation), we examined
the contributions of these enzymes to PAR2-induced
sensitization of TRPV4 Ca2+ signals in HBE and HEK cells
by using inhibitors.
Inhibitors of PLCβ (U73122; 10 µm), PKA (H-89;
10 µm) and classic and novel PKCs (GF109203X; blocks
PKCα, β, γ , δ,  and ζ ; 10 µm) all strongly inhibited
PAR2-AP-induced sensitization of Ca2+ responses to
4αPDD in HBE cells (Fig. 4A). Go¨6976 (0.1 µm), which
Figure 3. PAR-induced sensitization of TRPV4 Ca2+ signals
A, B, C, left panels show records of [Ca2+]i after challenge with PAR2-AP, PAR2-RP (both 100 µM) or vehicle (veh)
(A and B) or PAR1-AP, PAR1-RP (both 100 µM) or vehicle (C) at 50 s followed by 4αPDD (0.1 or 1 µM) or hypotonic
stimulus (260 mosmol l−1) at 350 s. Traces are from HBE cells (A) and HEK-TRPV4a cells (B and C). [Ca2+]i is
expressed as 340/380 nm emission ratio as a percentage of response measured at 50 s (prestimulus, 100%).
Right panels show [Ca2+]i responses as difference in 340/380 nm emission ratio between 350 s (prestimulus) and
550 s (maximal response). Pretreatment with PAR2-AP but not PAR1-AP increased Ca2+ responses to 4αPDD and
hypotonic stimulus, indicative of TRPV4 sensitization. ∗P < 0.05, ANOVA and Bonferroni’s test, n = 9 experiments.
blocks PKCα and β and PKD (Martiny-Baron et al. 1993;
Gschwendt et al. 1996), also inhibited this sensitization,
whereas Go¨6983 (0.1 µm), which blocks PKCα, β, γ ,
δ and ζ , but not PKD (Gschwendt et al. 1996), had
no effect. U73122, H-89 and Go¨6976 also inhibited
PAR2-AP-induced sensitization of Ca2+ responses to a
hypotonic stimulus in HBE cells, whereas GF109203X
and Go¨6983 had no effect (Fig. 4B). U73122, H-89,
GF109203X and Go¨6976, but not Go¨6983, inhibited
PAR2-induced sensitization of responses to 4αPDD in
HEK-FLPTREX-TRPV4a cells (Fig. 4C). Thus, in HBE
cells and HEK cells, activity of PLCβ, PKA, PKC and
possibly PKD are required for PAR2-induced sensitization
of responses to 4αPDD. In HBE cells, activity of PLCβ,
PKA and possibly PKD, but not PKC isozymes that are
sensitive to GF109203X, are required for PAR2-induced
sensitization of responses to a hypotonic stimulus. Our
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results are consistent with reports that 4αPDD and
hypotonic stimuli activate TRPV4 by distinct mechanisms
(Vriens et al. 2004).
TRPV4 is present in nociceptive neurons expressing
PAR2, CGRP and SP
PAR2 could regulate TRPV4-dependent neuronal activity
if these proteins are coexpressed in afferent neurons. PAR2
is present in DRG neurons expressing SP, CGRP and
TRPV1 (Steinhoff et al. 2000; Amadesi et al. 2004), but
it is not known if TRPV4 is expressed by these nociceptive
neurons. We used an antibody to the C-terminus of TRPV4
to localize this channel in rat DRG neurons. To characterize
the antibody, we stained HEK cells expressing wild-type
TRPV4a or TRPV4a with C-terminal HA.11 epitope. Both
immunoreactive HA.11 and TRPV4 were detected at the
plasma membrane and in intracellular locations (Fig. 5A).
The C-terminal HA.11 epitope interfered with interaction
of the TRPV4 antibody, which is directed to the C-terminus
of this channel, which precluded simultaneous localization
of HA.11 and TRPV4. Preabsorption of TRPV4 antibody
abolished the signal (Fig. 5A), and neither antibody stained
HEK cells expressing vector without TRPV4 insert (not
shown), confirming specific detection.
Immunoreactive TRPV4 was detected at varying levels
in the soma of rat DRG neurons, where it was present at the
plasma membrane (Fig. 5B, arrowheads), in cytoplasmic
vesicles and sometimes the nucleus (Fig. 5B, white arrows),
and was also detected in fibres. We did not determine the
number of neurons expressing immunoreactive TRPV4,
since the large variability in expression levels precluded
unequivocal discrimination between neurons expressing
the channel at low levels and neurons that did not
express detectable TRPV4. Some neurons expressing
TRPV4 also expressed immunoreactive PAR2, CGRP and
SP (Fig. 5B, white arrows). However, TRPV4 was also
found in neurons that did not contain these peptides
(Fig. 5B, yellow asterisks), and some peptide-containing
neurons did not express TRPV4 (Fig. 5B, yellow arrows).
TRPV4 expression was retained by DRG in short-term
culture, where immunoreactive TRPV4 was detected in
the soma and fibres (Fig. 5C). Some cultured neurons
expressing TRPV4 also expressed PAR2, CGRP and SP
(Fig. 5C). TRPV4 signals were abolished by preabsorption
of the antibody. Transcripts corresponding to mouse
(689 bp) and rat (723 bp) TRPV4 were amplified from
whole DRG, and identified by sequencing (Fig. 5D). Only
full-length TRPV4 was amplified. Thus, TRPV4 is present
in DRG neurons, some of which express PAR2, CGRP
and SP. Since cultured neurons maintain coexpression
of PAR2 and TRPV4, they may be used to study the
functional interactions of these proteins in nociceptive
neurons.
Figure 4. Mechanisms of PAR2-induced sensitization of TRPV4
Ca2+ signals
Effects of antagonists of signalling pathways on PAR2-induced
sensitization of Ca2+ signals to 4αPDD (0.1 or 1 µM) (A) and hypotonic
stimulus (260 mosmol l−1) (B) in HBE cells and to 4αPDD in
HEK-TRPV4a cells (C). Cells were pretreated with PAR2-AP or PAR2-RP
(both 100 µM) for 10 min before challenge with TRPV4 agonists.
U73122 (10 µM), H-89 (10 µM), GF109203X (GFX) 10 µM and
Go¨6976 (0.1 µM), but not Go¨6963 (0.1 µM), inhibited PAR2-induced
sensitization of Ca2+ responses to 4αPDD in HBE cells and
HEK-TRPV4a cells. U73122, H-89 and Go¨6976, but not GF109203X or
Go¨6963, inhibited PAR2-induced sensitization of Ca2+ responses to
hypotonic stimulus in HBE cells. Veh, vehicle; ∗P < 0.05; ANOVA
followed by Dunnett’s test; n = 8–12 experiments.
C© 2007 The Authors. Journal compilation C© 2007 The Physiological Society
724 A. D. Grant and others J Physiol 578.3
Agonists of PAR2 sensitize TRPV4 Ca2+ signalling
and currents in DRG neurons and HEK-TRPV4a cells
To determine if PAR2 agonists sensitize TRPV4 in
nociceptive neurons, we measured [Ca2+]i in rat DRG
neurons in short-term culture. In view of the divergent
mechanisms of PAR2-induced sensitization of responses
to 4αPDD and hypotonic stimuli that we identified in
epithelial cells, which require further experimentation to
fully investigate, we focused on sensitization of responses
to the TRPV4-selective agonist 4αPDD (Watanabe
et al. 2002) in neurons. 4αPDD (10 µm) caused a
gradual increase in [Ca2+]i in DRG neurons pretreated
for 20 min with PAR2-RP (10 µm, control) (Fig. 6a).
Pretreatment with PAR2-AP (10 µm, 20 min) caused a
>2-fold increase in the magnitude of Ca2+ response,
indicative of sensitization (Fig. 6b). Inhibition of PKA with
H-89 (10 µm) or PKC with GF109203X (1 µm) reduced
this sensitization (Fig. 6C).
To confirm that PAR2 activation sensitizes TRPV4,
we measured TRPV4 currents in acutely dissociated
mouse DRG neurons. In the whole-cell configuration,
we recorded current upon application of voltage ramp
from −100 to +100 mV. 4αPDD (10 µm) activated
Figure 5. Localization and expression of TRPV4 in HEK cells and DRG neurons
A, localization of TRPV4a transiently expressed in HEK cells by immunofluorescence using antibodies to HA.11
epitope or TRPV4. Both antibodies detected immunoreactive TRPV4. Control shows preabsorption of TRPV4 anti-
body with antigen used for immunization. B, localization of immunoreactive TRPV4, PAR2, CGRP or SP in sections of
rat DRG. TRPV4 was detected in the soma at the plasma membrane (white arrowheads) and in intracellular locations
(white arrows), and also in fibres (white arrows). White arrows show that some neurons coexpressed TRPV4 with
PAR2, CGRP or SP. Yellow arrows show that some neurons expressing CGRP or SP did not express TRPV4. Yellow
asterisks show that some neurons expressing TRPV4 did not express PAR2, CGRP or SP. Control shows preabsorption
of TRPV4 antibody. Scale bar = 10 µm c, Localization of immunoreactive TRPV4, PAR2, CGRP or SP in rat DRG after
2 days in culture. White arrows denote colocalization of TRPV4 with PAR2, CGRP or SP. Yellow arrows show that
some neurons expressing CGRP did not express TRPV4. Yellow asterisks show that neurons expressing TRPV4 did
not express CGRP or SP. Control shows preabsorption of TRPV4 antibody. Scale bar = 10 µm. D, RT-PCR of mouse
and rat DRG showing amplification of transcripts for TRPV4. There were no signals when reverse transcriptase (RT)
was omitted (control).
an outwardly rectifying current (Fig. 6D, left panel)
with current densities of −14.04 ± 2.89 pA pF−1 at
−80 mV and 27.40 ± 4.07 pA pF−1 at +80 mV (Fig. 6E),
and shifted the reversal potential toward positive.
Pretreatment with PAR2-AP (10 µm) for 20 min enhanced
the outward current (Fig. 6D, right panel), and increased
current densities by >2-fold to −52.96 ± 15.89 pA pF−1 at
−80 mV, and 62.27 ± 15.19 pA pF−1 at +80 mV (Fig. 6E).
PAR2-AP also increased the proportion of neurons that
responded to 4αPDD by activation of an outwardly
rectifying current from 66% in untreated neurons to
82% in neurons treated with PAR2-AP (Fig. 6F). Thus,
PAR2-AP sensitizes TRPV4 Ca2+ signals and currents in
DRG neurons, and activity of PKA and PKC is required
for this sensitization.
We similarly evaluated sensitization of TRPV4 currents
in HEK-FLPTREX-TRPV4a cells. 4αPDD (0.5 µm)
activated an outwardly rectifying whole-cell current
(Fig. 6G) with current densities of −28.51 ± 6.61 pA pF−1
at −80 mV and 58.41 ± 12.39 pA pF−1 at +80 mV
(Fig. 6H). Since these currents desensitized in the
continued presence of 4αPDD, cells were challenged
only once with 4αPDD, to avoid desensitization.
Pretreatment with PAR2-AP (100 µm) for 2 min
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resulted in >2-fold increase in the maximal current
induced by 4αPDD, and increased the currents by
>2-fold to −61.90 ± 6.52 pA pF−1 at −80 mV, and
120.80 ± 12.70 pA pF at +80 mV, indicative of TRPV4
sensitization (Fig. 6H). Inhibition of PKA with H-89
(3 µm) or PKC with calphostin C (2 µm) reduced the
current density at +80 mV following PAR2-AP from
120.80 ± 12.70 pA pF−1 to 47.50 ± 30.28 pA pF−1 with
H-89 and 26.00 ± 11.98 pA pF−1 with calphostin C
(Fig. 6I). Thus, PAR2 sensitizes TRPV4 Ca2+ signals and
currents in DRG neurons and HEK-FLPTREX-TRPV4a
cells by PKC- and PKA-dependent processes.
Agonists of PAR2 sensitize TRPV4-stimulated release
of neuropeptides
The release of SP and CGRP from the central projections
of nociceptive DRG neurons in the dorsal horn correlates
with pain transmission, and sensitization of this process
may enhance pain transmission. The TRPV1 agonist
capsaicin strongly stimulates SP and CGRP release within
the dorsal horn (Mantyh et al. 1995; Marvizon et al. 1997,
2003; Amadesi et al. 2004). Agonists of PAR2 also stimulate
the release of CGRP and SP from nociceptive neurons
(Steinhoff et al. 2000), and potentiate TRPV1-induced
peptide release in the dorsal horn (Amadesi et al. 2004).
However, it is not known if TRPV4 agonists stimulate
neuropeptide release, and whether PAR2 sensitizes this
effect. To examine these possibilities, we studied segments
of rat spinal cord.
We first determined if TRPV4 was present in nerve fibres
in superficial laminae of the dorsal horn that contain SP
and CGRP. Immunoreactive TRPV4 was detected in cells
bodies and in punctate structures that may represent nerve
fibres in the superficial and deeper laminae of the dorsal
horn of rat spinal cord (Fig. 7). Immunoreactive CGRP
and SP were prominently detected in nerve fibres in super-
ficial laminae I and II of the dorsal horn. Some fibres
containing immunoreactive CGRP and SP also contained
immunoreactive TRPV4 (Fig. 7). Thus, TRPV4 is present
in neuropeptide-containing nerve fibres in the dorsal horn
of the spinal cord.
To determine if TRPV4 agonists induce release of CGRP
and SP, we incubated slices of dorsal horn of the rat spinal
cord with 4αPDD or hypotonic solution, and measured
release of immunoreactive CGRP and SP. 4αPDD
(10 µm) stimulated a >9-fold increase in CGRP release
and a >4-fold increase in SP release over basal values
(basal: CGRP, 2.0 ± 1.0 fmol g (20 min)−1, SP, 1.0 ±
1.0 fmol g (20 min)−1; 4αPDD: CGRP, 18.7 ± 4.5 fmol g
(20 min)−1; SP, 4.2 ± 1.2 fmol g (20 min)−1) (Fig. 8A). A
higher concentration of 4αPDD (100 µm) produced a
greater response (CGRP, 42.5 ± 10.2 fmol g (20 min)−1;
SP, 8.9 ± 1.8 fmol g (20 min)−1). Hypotonic solution
(228 mosmol l−1) stimulated an 18-fold increase
in CGRP release and a >10-fold increase in SP
release (CGRP, 82.4 ± 5.6 fmol g (20 min)−1; SP,
19.3 ± 2.6 fmol g (20 min)−1) (Fig. 8B). Removal of
extracellular Ca2+ ions, and capsaicin-desensitization of
tissues inhibited the stimulatory effects of 4αPDD and
hypotonic solution. Thus, TRPV4 agonists stimulate
the Ca2+-dependent release of proinflammatory and
nociceptive peptides from capsaicin-sensitive afferent
nerve endings.
A consequence of PAR2-induced sensitization of TRPV4
may be to enhance the release of neuropeptides. To
examine this possibility, we preincubated segments of the
dorsal horn of the rat spinal cord with PAR2-AP, PAR2-RP
(10 µm) or vehicle for 20 min, washed the segments, and
then measured release of CGRP and SP in response to
incubation of segments with 4αPDD (10 µm) or hypotonic
solution (228 mosmol l−1). PAR2-AP enhanced the release
of immunoreactive CGRP and SP to 4αPDD by >2-fold
compared to PAR2-RP or vehicle (Fig. 8C). Similarly,
PAR2-AP enhanced release of immunoreactive CGRP and
SP to a hypotonic stimulus (Fig. 8D). Thus, agonists
of PAR2 sensitize TRPV4-induced release of nociceptive
peptides in the dorsal horn.
TRPV4 mediates PAR2-induced hypersensitivity
to a mechanical stimulus
PAR2 agonists cause mechanical allodynia and hyper-
algesia by unknown mechanisms (Vergnolle et al. 2001;
Coelho et al. 2002). Since deletion and downregulation
of TRPV4 results in diminished pain to mechanical
and hypoosmotic stimuli (Alessandri-Haber et al. 2003,
2006; Liedtke & Friedman, 2003; Suzuki et al. 2003), we
examined the effects of PAR2-AP on mechanical allodynia
and hyperalgesia in TRPV4+/+ and TRPV4−/− mice. We
have previously reported that the hyperalgesic effect of
PAR2-AP requires expression of PAR2, and that PAR2-RP
has no effect, confirming specificity (Vergnolle et al.
2001).
Intraplantar injection of 4αPDD (10 µl of 50 µm
solution) or PAR2-AP (1 µg in 10 µl saline) in TRPV4+/+
mice produced an increase in paw withdrawal frequency
to stimulation with a 0.173 mN von Frey hair, compared to
basal measurements (Fig. 9A and B). These increases were
not observed in TRPV4−/− mice. In contrast, intraplantar
injection of hypotonic solution (10 µl of 17 mosmol l−1)
did not increase the number of paw withdrawals in
TRPV4+/+ or TRPV4−/− mice (Fig. 9B). Thus, TRPV4
is required for PAR2- and 4αPDD-induced increases in
mechanical sensitivity, which is indicative of mechanical
allodynia and hyperalgesia.
To determine if activation of PAR2 sensitizes pain
responses to agonists of TRPV4, we administered PAR2-AP
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Figure 6. PAR2-induced sensitization of TRPV4 Ca2+ signals and currents in DRG neurons (A–F) and
HEK-FLPTREX-TRPV4a cells (G–I)
Neurons were pretreated for 20 min and HEK-FLPTREX-TRPV4a cells for 2 min with PAR2-AP, PAR2-RP or vehicle
(Veh) before challenge with 4αPDD. A–C, [Ca2+]i records in rat DRG neurons. A, records of [Ca2+]i in DRG neurons
challenged with 4αPDD (10 µM). B, maximal [Ca2+]i responses to 4αPDD (10 µM) expressed as percentage response
in neurons pretreated with PAR2-RP (100%). Pretreatment with PAR2-AP (10 µM) increased 4αPDD-stimulated Ca2+
response, indicative of TRPV4 sensitization (∗P < 0.05, Student’s t test). C, effects of inhibitors of second messenger
C© 2007 The Authors. Journal compilation C© 2007 The Physiological Society
J Physiol 578.3 PAR2-induced mechanical hyperalgesia 727
(1 µg in 10 µl saline) 5 min before 4αPDD (10 µl of 50 µm
solution) or a hypotonic solution (10 µl of 17 mosmol l−1).
In TRPV4+/+ mice, preinjection of PAR2-AP caused a
>2-fold increase in the frequency of paw withdrawal
to 4αPDD alone (Fig. 9A), and a >3-fold increase in
the frequency of paw withdrawal to hypotonic solution
alone (Fig. 9B). This sensitization was not present in
TRPV4−/− mice. Thus, PAR2-AP sensitizes TRPV4 to
increase sensitivity of the paw to a mechanical stimulus,
indicative of mechanical allodynia and hyperalgesia.
Discussion
Our results show, for the first time, that TRPV4
mediates PAR2-induced mechanical allodynia and hyper-
algesia. PAR2 sensitizes TRPV4 Ca2+ signals and currents
in cell lines and afferent neurons by mechanisms
requiring activity of PLCβ, PKA, PKC and perhaps
PKD. TRPV4 agonists promote SP and CGRP release
from afferent nerves in the spinal cord, where
they can mediate nociceptive transmission. PAR2
sensitizes both TRPV4-mediated neuropeptide release and
TRPV4-induced mechanical hyperalgesia, and TRPV4
deletion prevents PAR2-induced mechanical hyperalgesia.
Thus, we have identified a novel mechanism by
which proteases that are generated during injury and
inflammation cleave PAR2 on afferent nerve endings to
activate second messenger kinases that sensitize TRPV4
Ca2+ signals; this sensitization enhances the release of
nociceptive neuropeptides at the spinal level and causes
mechanical allodynia and hyperalgesia (Fig. 10).
PAR-mediated sensitization of TRPV4
The observation that afferent nerves coexpress immuno-
reactive TRPV4 and PAR2 suggests that PAR2 can sensitize
TRPV4 within an individual neuron, without involvement
of other cell types. HBE cells also coexpressed TRPV4
and PAR2, providing a convenient cell line in which to
study interactions between these proteins. We identified
three TRPV4 isoforms in these cells, corresponding to
sequences also identified in human tracheal epithelial cells
(Arniges et al. 2006). In this study, only full-length TRPV4
kinases on PAR2-induced sensitization of Ca2+ signals to 4αPDD. Results are expressed as percentage of response
to 4αPDD in neurons pretreated with PAR2-AP (100%). H-89 (10 µM) and GF109203X (GFX) 1 µM inhibited
PAR2-induced sensitization of Ca2+ responses to 4αPDD (∗P < 0.05, ANOVA and Dunnett’s test). D–F, whole-cell
currents of mouse DRG neurons. D, whole-cell currents recorded during voltage ramp (−100 mV to +100 mV
every 15 s) before and during application of 4αPDD (10 µM). E, current densities at −80 mV and +80 mV. PAR2-AP
(10 µM) increased 4αPDD-mediated current density (∗∗P < 0.01; ∗P < 0.02, Student’s t test). F, proportion of
neurons that responded to 4αPDD (10 µM) by activation of an outwardly rectifying current. G–H, whole-cell currents
of HEK-FLPTREX-TRPV4a. G, whole-cell currents recorded during voltage ramp (−100 mV to +100 mV every 15 s)
before and during application of 4αPDD (0.5 µM). H, current densities at −80 mV and +80 mV. PAR2-AP (100 µM)
increased 4αPDD-mediated current density (∗∗P < 0.01; ∗P < 0.05, Student’s t test). I, effects of antagonists of
signalling pathways on PAR2-induced sensitization of currents to 4αPDD. H-89 (3 µM) and calphostin C (CaC) 2 µM
inhibited sensitization (∗P < 0.05; Student’s t test). In A–I, numbers in parentheses refer to the number of cells.
Figure 7. Localization of immunoreactive TRPV4, CGRP or SP in
dorsal horn of rat spinal cord
Control shows preabsorption of TRPV4 antibody with antigen used for
immunization. White arrows show colocalization of TRPV4 with CGRP
and SP in some fibres of superficial laminae I and II. Scale bar = 10 µm.
was detected at the plasma membrane, whereas truncated
isoforms, lacking ankyrin domains, were retained in
the endoplasmic reticulum (Arniges et al. 2006). In
contrast, we found that all TRPV4 isoforms were present
at the plasma membrane and in intracellular locations
when transiently expressed in HEK cells. However, in
both studies, only full-length TRPV4 protein with three
complete ankyrin domains responded to 4αPDD or a
hypotonic stimulus. The function of the other isoforms
is unknown.
Expression of TRPV4a in HEK cells conferred
responsiveness to 4αPDD and hypotonic stimuli,
suggesting that these agents specifically activate TRPV4.
Pretreatment of HBE or HEK-TRPV4a cells with PAR2-AP
enhanced Ca2+ signals to 4αPDD and hypotonic stimuli,
indicating that PAR2 sensitizes TRPV4. PAR2 also
sensitized TRPV4 currents in HEK-FLPTREX-TRPV4a
cells. PAR1-AP increased [Ca2+]i in HEK-TRPV4a cells to
a similar level as PAR2-AP, but did not affect the responses
to 4αPDD, indicating that PAR1 does not sensitize TRPV4.
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Unlike PAR2 agonists, PAR1 agonists do not cause thermal
or mechanical hyperalgesia (Asfaha et al. 2002) and do not
sensitize TRPV1 (Amadesi et al. 2004). Thus, sensitization
of TRPV4 is specific to PAR2, rather than being a general
effect of PARs that do not influence nociception.
If PAR2-mediated sensitization of TRPV4 is relevant
to mechanical hyperalgesia, it should occur in the DRG
neurons that transduce painful mechanical stimuli. We
observed that PAR2-AP enhanced 4αPDD-induced Ca2+
signals and currents in isolated DRG neurons, and also
increased the proportion of responsive neurons. These
results confirm that DRG neurons coexpress PAR2 and
TRPV4, and demonstrate a functional interaction between
these proteins that increases the sensitivity of TRPV4 to its
agonist. This interaction occurs at the level of individual
neurons, suggesting that it is mediated through activation
of intracellular signalling cascades. In a similar manner,
PAR2 agonists also enhance capsaicin Ca2+ signals and
currents in DRG neurons and increase the proportion of
capsaicin-responsive neurons, indicative of sensitization
of TRPV1 (Amadesi et al. 2004; Amadesi et al. 2006; Dai
et al. 2004).
We have previously reported that >60% of DRG
neurons express immunoreactive PAR2 and respond to
Figure 8. TRPV4-mediated peptide release from rat dorsal horn
Effects of 4αPDD (10–100 µM) (A) and hypotonic stimulus (228 mosmol l−1) (B) on release of CGRP (left panels)
and SP (right panels) from superfused slices of dorsal spinal cord. −[Ca2+]o denotes Ca2+-free solution and Caps
denotes pretreatment with capsaicin. 4αPDD and hypotonic stimulus induced release of CGRP and SP, and release
required extracellular Ca2+ ions and was prevented by capsaicin pretreatment. ∗P < 0.05 compared to vehicle;
ANOVA and Bonferroni’s test. C and D, PAR2-induced sensitization of neuropeptide release from dorsal spinal cord.
Effects of preincubation with PAR2-AP, PAR2-RP (both 10 µM) or vehicle for 20 min on release of immunoreactive
CGRP (left panels) and SP (right panels) in response to 4αPDD (C) or hypotonic stimulus (D). Pretreatment with
PAR2-AP increased release of CGRP and SP in response to 4αPDD and hypotonic stimulus, indicative of TRPV4
sensitization. ∗P < 0.05 compared to vehicle; ANOVA followed by Bonferroni’s test. n = 6–9 experiments.
PAR2 agonists with increased [Ca2+]i (Steinhoff et al.
2000). Although variability in the levels of immuno-
reactive TRPV4 precluded accurate quantification of
the proportion of TRPV4-expressing neurons, >60%
of DRG neurons responded to 4αPDD with a
detectable current, and this proportion was increased by
pretreatment with PAR2-AP, indicative of sensitization.
Thus, similar proportions of neurons express functional
PAR2 and TRPV4, and we also observed that immuno-
reactive PAR2 and TRPV4 are frequently coexpressed.
PAR2 agonists may directly regulate TRPV4 activity
in these neurons. However, some neurons containing
immunoreactive TRPV4 did not express detectable
PAR2 (or CGRP or SP), and it is possible that some
PAR2-stained neurons do not express TRPV4. PAR2
may regulate these neurons by TRPV4-independent
mechanisms, which remain to be characterized. Other
mechanisms may regulate TRPV4 in neurons that do
not express PAR2. We detected immunoreactive TRPV4
at the plasma membrane, in cytosolic vesicles and
sometimes in the nucleus of DRG neurons. TRPV4 at
the plasma membrane may be a target for regulation by
PAR2 and other inflammatory agents, which could also
control TRPV4 trafficking between the plasma membrane
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and vesicles. A function of TRPV4 in the nucleus is
unknown.
Mechanisms of PAR2-induced sensitization of TRPV4
PAR2 couples through Gαq/11 to PLCβ and the release
of inositol trisphosphate and diacylglycerol (Bohm et al.
1996a), and in afferent neurons PAR2 activates PKA,
PKC (Amadesi et al. 2006) and PKD (N.W. Burnett,
unpublished observation). We examined the contribution
of these signalling pathways to PAR2-induced sensitization
of TRPV4 Ca2+ signals and currents in cell lines
and neurons. As expected, the PLCβ inhibitor U73122
abolished PAR2-induced sensitization of responses to
4αPDD in HBE and HEK-TRPV4a cells. The PKA
inhibitor H-89, the broad-spectrum PKC inhibitors
GF109203X and calphostin C, and Go¨6976, which blocks
PKCα, β and PKD (Martiny-Baron et al. 1993; Gschwendt
et al. 1996), also inhibited PAR2-induced sensitization
of responses to 4αPDD. The lack of effect of Go¨6983,
which blocks PKCα, β, γ , δ and ζ but not PKD
(Gschwendt et al. 1996), suggests that the inhibitory effects
of Go¨6976 are due to an action on PKD, which requires
additional investigation. Together, these data suggest
that PAR2-induced sensitization of TRPV4 responses to
4αPDD requires activation of PLCβ, followed by PKA,
PKC and PKD activity. It remains to be determined
whether these kinases act sequentially or in parallel. It is
also unknown whether PKA, PKC and PKD phosphorylate
and thereby sensitize TRPV4, as they do for TRPV1
(Lopshire & Nicol, 1998; Premkumar & Ahern, 2000;
Vellani et al. 2001; Bhave et al. 2002; Mohapatra & Nau,
2003; Wang et al. 2004). In support of our results, PLCβ,
PKA and PKC mediate PAR2-induced sensitization of
TRPV1 (Amadesi et al. 2004; Dai et al. 2004; Amadesi et al.
2006).
Slightly different mechanisms mediate PAR2-induced
sensitization of TRPV4 responses to hypotonic stimulus.
Although antagonism of PLCβ and PKA prevented
sensitization of responses to hypotonic stimulus in HBE
cells, the broad-spectrum PKC inhibitor GF109203X
was without effect. Further investigations, using selective
approaches to antagonize activity or expression of second
messenger systems, are required to elucidate the precise
mechanisms of this sensitization. However, our results
showing differences in the mechanisms of PAR2-induced
sensitization of TRPV4 responses to hypotonic stimuli and
4αPDD are consistent with the view that these agonists
activate TRPV4 by different mechanisms (Vriens et al.
2004).
PAR2-induced sensitization of TRPV4-mediated
peptide release and mechanical hyperalgesia
Release of SP and CGRP from the central projections
of nociceptive DRG neurons within the dorsal horn
correlates with nociceptive behaviour, and agonists of
both TRPV1 (Mantyh et al. 1995; Marvizon et al. 1997,
2003; Amadesi et al. 2004) and PAR2 (Steinhoff et al.
2000) promote SP and CGRP release from these fibres.
We detected immunoreactive TRPV4 in nerve fibres of
superficial laminae of the dorsal horn that also contained
immunoreactive SP and CGRP. These fibres probably
represent the central projections of primary spinal afferent
neurons, although additional experiments are required to
Figure 9. Role of TRPV4 in PAR2-induced mechanical
hyperalgesia
Frequency of paw withdrawal to stimulation with a von Frey hair
under basal conditions, after intraplantar injection of 4αPDD or
PAR2-AP alone, or after injection of PAR2-AP followed 5 min later by
4αPDD (A), and distilled water or PAR2-AP alone, or after injection of
PAR2-AP followed 5 min later by distilled water (B). When given alone,
4αPDD (10 µl of 50 µM solution) and PAR2-AP (1 µg in 10 µl saline),
but not hypotonic stimulus (10 µl of 17 mosmol l−1), increased the
frequency of paw withdrawal in TRPV4+/+ but not TRPV4−/− mice,
indicating that TRPV4 mediates 4αPDD- and PAR2-AP-induced
mechanical hyperalgesia. Preinjection of PAR2-AP enhanced responses
to 4αPDD and hypotonic stimulus in TRPV4+/+ but not TRPV4−/−
mice, indicating that PAR2 sensitizes TRPV4 to cause mechanical
hyperalgesia. ∗∗∗P < 0.001; ∗P < 0.05 compared to vehicle;
†††P < 0.001 compared to TRPV4+/+. ANOVA and Bonferroni’s test.
N = 6–9 animals.
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confirm this hypothesis. The TRPV4 agonists 4αPDD and
hypotonic solutions stimulated release of both neuro-
peptides from slices of the dorsal spinal cord, consistent
with a role of TRPV4 in nociception. This release required
extracellular Ca2+ ions, indicative of regulated exocytosis
from spinal nociceptive afferent fibres. Pretreatment with
capsaicin prevented the effects of TRPV4 agonists on
peptide release, confirming that TRPV4 agonists stimulate
peptide secretion from nociceptive nerve fibres that express
TRPV1. We also detected immunoreactive TRPV4 on
unidentified neurons of the dorsal horn, and thus cannot
exclude the possibility that TRPV4 agonists stimulated
peptide release by indirect mechanisms. The identity of
these TRPV4-expressing neurons and the role of TRPV4
in these cells remains to de determined.
PAR2-AP increased the release of SP and CGRP in
response to 4αPDD or hypotonic saline. Thus, PAR2
not only sensitizes TRPV4 Ca2+ signals and currents
in DRG neurons, but also sensitizes TRPV4-dependent
peptide release from intact nerve fibres. Increased peptide
release following PAR2-mediated TRPV4 sensitization
may contribute to enhanced mechanical nociception by
facilitating central nociceptive transmission. In support of
these results, PAR2 agonists also sensitize TRPV1-mediated
SP and CGRP release from the dorsal horn (Amadesi et al.
2004).
Intraplantar injection of PAR2-AP alone increased paw
withdrawal responses to a mechanical stimulus, and
enhanced responses to 4αPDD and hypotonic solution,
indicating that PAR2 induces mechanical allodynia and
Figure 10. Proposed model of protease-induced mechanical hyperalgesia
Proteases that are generated during inflammation (1) activate PAR2 on afferent nerve endings in peripheral tissues
(2). PAR2 couples to activation of second messenger kinases (3) that may phosphorylate and sensitize TRPV4 (4),
resulting in enhanced influx of Na+ and Ca2+ ions (5) and elevated release of CGRP and SP in the dorsal horn in
response to mechanical stimuli (6). CGRP and SP activate their receptors on spinal neurons (CGRP, calcitonin-like
receptor (CLR) and receptor activity-modifying protein 1 (RAMP1); SP, neurokinin 1 receptor (NK1R)), resulting in
enhanced transmission of nociceptive signals and mechanical hyperalgesia.
hyperalgesia. These responses were not present in
TRPV4-deficient mice and thus depend on the presence
of this channel. Hypotonic solution alone had no effect on
paw withdrawal in the absence of a sensitizing stimulus,
in agreement with our previous finding that pretreatment
with prostaglandin E2 is necessary to induce nocifensive
responses to a hypotonic stimulus (Alessandri-Haber
et al. 2003). In contrast, injection of 4αPDD alone was
sufficient to cause increased paw withdrawal in wild-type
but not TRPV4-deficient mice. These data provide novel
evidence that 4αPDD selectively activates TRPV4 in
vivo, and possibly that hypotonic stimuli and 4αPDD
activate TRPV4 by distinct mechanisms in live animals, as
previously suggested in heterologous expression systems
(Vriens et al. 2004).
Although our results suggest that PAR2 agonists can
sensitize TRPV4 on primary spinal afferent neurons to
enhance peptide release and cause mechanical hyper-
algesia, we cannot exclude the possibility that PAR2
also sensitizes TRPV4 on other cell types to enhance
nociception. Keratinocytes highly express PAR2 and
TRPV4 (Steinhoff et al. 1999; Chung et al. 2003, 2004).
These cells receive a rich sensory innervation and have been
proposed to participate in TRPV4-dependent thermo-
sensation (Lee et al. 2005). Indeed, our results show
that PAR2 agonist strongly sensitizes TRPV4 in airway
epithelial cells, and similar sensitization in keratinocytes or
enterocytes could contribute to mechanical hyperalgesia
in the skin and intestine. Additional experiments are
necessary to investigate this possibility.
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General mechanisms by which PAR2 regulates
afferent neurons
PAR2 may regulate the activity of primary spinal afferent
neurons by several mechanisms. The mechanism that
we describe, by which PAR2 activates second messenger
kinases that sensitize TRPV4 Ca2+ signals and currents
to enhance release of nociceptive peptides in the spinal
cord and induce mechanical hyperalgesia and allodynia in
vivo (Fig. 10), resembles the mechanism by which PAR2
sensitizes TRPV1 to cause hyperalgesia to thermal stimuli
(Amadesi et al. 2004, 2006; Dai et al. 2004). Agonists
of PAR2 sensitize TRPV1 Ca2+ signals and currents and
enhance release of SP and CGRP from the dorsal horn
of the spinal cord (Amadesi et al. 2004; Dai et al. 2004).
Antagonism or deletion of TRPV1 inhibits PAR2-induced
hyperalgesia to thermal stimuli, indicating an essential
role for TRPV1 in this process (Amadesi et al. 2004).
PAR2 agonists promote phosphorylation of TRPV1, and
sensitization of TRPV1 depends on activity of PLCβ, PKA
and PKC (Amadesi et al. 2004; Amadesi et al. 2006; Dai
et al. 2004).
In addition to PAR2 agonists, other inflammatory agents
sensitize TRPV1 and TRPV4, including bradykinin, ATP,
prostaglandin E2 and nerve growth factor (Lopshire &
Nicol, 1997; Chuang et al. 2001; Tominaga et al. 2001;
Vellani et al. 2001; Alessandri-Haber et al. 2003, 2005;
Alessandri-Haber et al. 2006). Mechanisms of sensitization
include PKC- and PKA-dependent phosphorylation of
TRPV1, which modify channel gating and desensitization
(Lopshire & Nicol, 1998; Cesare et al. 1999; Premkumar
& Ahern, 2000; Bhave et al. 2002; Numazaki et al.
2002; Rathee et al. 2002; Mohapatra & Nau, 2003).
Additional mechanisms of TRPV1 sensitization include
altered interactions of TRPV1 with the endogenous
inhibitor phospatidylinositol-4,5-bisphosphate (Chuang
et al. 2001; Prescott & Julius, 2003), and PKC- and Src
kinase-dependent trafficking of TRPV1 to the plasma
membrane (Morenilla-Palao et al. 2004; Zhang et al.
2005). It remains to be determined whether alterations
in phosphorylation and membrane translocation mediate
PAR2-induced sensitization of TRPV4, and whether PAR2
agonists also sensitize other TRP channels of afferent
neurons.
PAR2 agonists also transiently depolarize primary
spinal afferent neurons and induce a sustained hyper-
excitability to depolarizing stimuli (Amadesi et al. 2004).
This hyperexcitability does not involve sensitization of
TRPV channels, but rather involves suppression of
delayed rectifier IK currents (N.W. Burnett and S. Vanner
unpublished observation). Thus, PAR2 can regulate
activity of afferent neurons by several mechanisms.
These mechanisms, by which PAR2 agonists signal
to primary spinal afferent neurons to sensitize TRPV1
and TRPV4 and suppress IK currents, may be relevant
in painful inflammatory diseases such as arthritis,
inflammatory bowel disease and irritable bowel syndrome,
where multiple PAR2-activating proteases are produced
(Nakano et al. 1999; Tarlton et al. 2000; Mohammed et al.
2003; Barbara et al. 2004; Hansen et al. 2005). Thus,
antagonists of PAR2, second messenger kinases and TRPV
channels may be promising therapies for inflammatory
hyperalgesia.
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